Indeed, testing for common IPMN mutations (e.g., KRAS and GNAS) in cystic fluid achieved 96% sensitivity and 100% specificity in making a diagnosis of IPMN. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.